Cargando…

Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes

Detalles Bibliográficos
Autor principal:	DeFronzo, Ralph A.
Formato:	Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2011
Materias:	Editorial Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3064029/ https://www.ncbi.nlm.nih.gov/pubmed/21447659 http://dx.doi.org/10.2337/dc11-0064

Ejemplares similares

Is Incretin-Based Therapy Ready for the Care of Hospitalized Patients With Type 2 Diabetes?: The time has come for GLP-1 receptor agonists!
por: Schwartz, Stanley, et al.
Publicado: (2013)

Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment
por: Triplitt, Curtis, et al.
Publicado: (2010)

From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
por: DeFronzo, Ralph A.
Publicado: (2009)

Bromocriptine in type 2 diabetes mellitus
por: Shivaprasad, C., et al.
Publicado: (2011)

Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm
por: Abdul-Ghani, Muhammad, et al.
Publicado: (2017)

Dopamine D2 receptor agonist, bromocriptine, remodels adipose tissue dopaminergic signalling and upregulates catabolic pathways, improving metabolic profile in type 2 diabetes
por: Tavares, G., et al.
Publicado: (2021)

Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2022)

Bromocriptine-QR Therapy Reduces Sympathetic Tone and Ameliorates a Pro-Oxidative/Pro-Inflammatory Phenotype in Peripheral Blood Mononuclear Cells and Plasma of Type 2 Diabetes Subjects
por: Cincotta, Anthony H., et al.
Publicado: (2022)

Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2009)

Bromocriptine approved as the first medication to target dopamine activity to improve glycemic control in patients with type 2 diabetes
por: Via, Michael A, et al.
Publicado: (2010)

Type 2 Diabetes Can Be Prevented With Early Pharmacological Intervention
por: DeFronzo, Ralph A., et al.
Publicado: (2011)

Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009
por: DeFronzo, R. A.
Publicado: (2010)

Visceral fat dominant distribution in male type 2 diabetic patients is closely related to hepatic insulin resistance, irrespective of body type
por: Miyazaki, Yoshinori, et al.
Publicado: (2009)

Plasma Glucose Concentration and Prediction of Future Risk of Type 2 Diabetes
por: Abdul-Ghani, Muhammad A., et al.
Publicado: (2009)

Incidence of heart valve disease in women treated with the ergot-derived dopamine agonist bromocriptine
por: Clausen, Marianne F., et al.
Publicado: (2021)

Central sympatholytics prolong survival in experimental sepsis
por: Hofer, Stefan, et al.
Publicado: (2009)

Glucose lowering and vascular protective effects of cycloset added to GLP‐1 receptor agonists in patients with type 2 diabetes
por: Alatrach, Mariam, et al.
Publicado: (2018)

Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2013)

The Dopamine Agonist Bromocriptine Differentially Affects Fronto-Striatal Functional Connectivity During Working Memory
por: Wallace, Deanna L., et al.
Publicado: (2011)

From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes
por: Mosenzon, Ofri, et al.
Publicado: (2021)

Bromocriptine mesylate: FDA-approved novel treatment for type-2 diabetes
por: Mahajan, Rajiv
Publicado: (2009)

Targeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition
por: Herat, Lakshini Y., et al.
Publicado: (2022)

The Impact of Vitamin D Deficiency on Retinopathy and Hearing Loss among Type 2 Diabetic Patients
por: Bener, Abdulbari, et al.
Publicado: (2018)

Evaluation of the efficacy and safety of bromocriptine QR in type 2 diabetes
por: Ramteke, Karuna Balwant, et al.
Publicado: (2011)

Brain Dopamine–Clock Interactions Regulate Cardiometabolic Physiology: Mechanisms of the Observed Cardioprotective Effects of Circadian-Timed Bromocriptine-QR Therapy in Type 2 Diabetes Subjects
por: Cincotta, Anthony H.
Publicado: (2023)

Bromocriptine as a Potential Glucose-lowering Agent for the Treatment of Prolactinoma with Type 2 Diabetes
por: Oshige, Tamami, et al.
Publicado: (2019)

Effect of Bromocriptine-QR (a Quick-Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects
por: Gaziano, J. Michael, et al.
Publicado: (2012)

Effect of Bromocriptine‐QR (a Quick‐Release Formulation of Bromocriptine Mesylate) on Major Adverse Cardiovascular Events in Type 2 Diabetes Subjects
Publicado: (2015)

One-Hour Plasma Glucose Concentration and the Metabolic Syndrome Identify Subjects at High Risk for Future Type 2 Diabetes
por: Abdul-Ghani, Muhammad A., et al.
Publicado: (2008)

Transcriptomics in type 2 diabetes: Bridging the gap between genotype and phenotype
por: Jenkinson, Christopher P., et al.
Publicado: (2015)

Endovascular renal denervation: a novel sympatholytic with relevance to chronic kidney disease
por: Hoye, Neil A., et al.
Publicado: (2014)

Identification and validation of the dopamine agonist bromocriptine as a novel therapy for high-risk myelodysplastic syndromes and secondary acute myeloid leukemia
por: Liberante, Fabio Giuseppe, et al.
Publicado: (2015)

Empagliflozin Treatment Is Associated With Improved β-Cell Function in Type 2 Diabetes Mellitus
por: Al Jobori, Hussein, et al.
Publicado: (2018)

Mechanism of Action of Inhaled Insulin on Whole Body Glucose Metabolism in Subjects with Type 2 Diabetes Mellitus
por: Mehta, Rucha J., et al.
Publicado: (2019)

Fasting Versus Postload Plasma Glucose Concentration and the Risk for Future Type 2 Diabetes: Results from the Botnia Study
por: Abdul-Ghani, Muhammad A., et al.
Publicado: (2009)

Minimal Contribution of Fasting Hyperglycemia to the Incidence of Type 2 Diabetes in Subjects With Normal 2-h Plasma Glucose
por: Abdul-Ghani, Muhammad A., et al.
Publicado: (2010)

Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control: A randomized, double-blind, placebo-controlled study
por: DeFronzo, Ralph A., et al.
Publicado: (2008)

Effects of Exenatide Plus Rosiglitazone on β-Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin
por: DeFronzo, Ralph A., et al.
Publicado: (2010)

Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?
por: Abdul-Ghani, Muhammad, et al.
Publicado: (2017)

Comment on Piccinini and Bergman. The Measurement of Insulin Clearance. Diabetes Care 2020;43:2296–2302
por: Gastaldelli, Amalia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_huk0pme1lge72d037jvrhh3pg6